David B. Olsen

10.0k total citations
180 papers, 6.3k citations indexed

About

David B. Olsen is a scholar working on Infectious Diseases, Molecular Biology and Epidemiology. According to data from OpenAlex, David B. Olsen has authored 180 papers receiving a total of 6.3k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Infectious Diseases, 65 papers in Molecular Biology and 44 papers in Epidemiology. Recurrent topics in David B. Olsen's work include HIV/AIDS drug development and treatment (60 papers), Hepatitis C virus research (37 papers) and Biochemical and Molecular Research (26 papers). David B. Olsen is often cited by papers focused on HIV/AIDS drug development and treatment (60 papers), Hepatitis C virus research (37 papers) and Biochemical and Molecular Research (26 papers). David B. Olsen collaborates with scholars based in United States, Denmark and Germany. David B. Olsen's co-authors include Steven S. Carroll, John Vissing, Bengt Saltin, Fritz Eckstein, Mark W. Stahlhut, Fritz Benseler, José González‐Alonso, Helle Aurup, Wolfgang A. Pieken and Tina D. Jeppesen and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of the American Chemical Society.

In The Last Decade

David B. Olsen

176 papers receiving 6.0k citations

Peers

Countries citing papers authored by David B. Olsen

Since Specialization

Citations

This map shows the geographic impact of David B. Olsen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David B. Olsen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David B. Olsen more than expected).

Fields of papers citing papers by David B. Olsen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David B. Olsen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David B. Olsen. The network helps show where David B. Olsen may publish in the future.

Co-authorship network of co-authors of David B. Olsen

This figure shows the co-authorship network connecting the top 25 collaborators of David B. Olsen. A scholar is included among the top collaborators of David B. Olsen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David B. Olsen. David B. Olsen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Structure–activity analysis of imino‐pyrimidinone‐fused pyrrolidines aids the development of dual plasmepsin V and plasmepsin X inhibitors 2025 ·FEBS Journal ·Anthony N. Hodder, Brad E. Sleebs, G. W. Adams, Sh Rezazadeh, Anna Ngo, Kate E. Jarman, S.W. Scally, Peter E. Czabotar, Hongwu Wang, John A. McCauley, David B. Olsen, Alan F. Cowman	0
2	Orally available nucleoside analog UMM-766 provides protection in a murine model of orthopox disease 2024 ·Microbiology Spectrum ·Rajini Mudhasani, Joseph W. Golden, Gregory C. Adam, (unknown), Krishna P. Kota, (unknown), Corey R. Quackenbush, Julie P. Tran, (unknown), Janice A. Williams, Xiankun Zeng, David B. Olsen, Linda A. Lieberman, Christopher W. Boyce, (unknown), J. Matthew Meinig, Rekha G. Panchal, Eric M. Mucker	2
3	Activity of Tricyclic Pyrrolopyrimidine Gyrase B Inhibitor against Mycobacterium abscessus 2022 ·Antimicrobial Agents and Chemotherapy ·(unknown), Dereje A. Negatu, (unknown), Randy R. Miller, Christopher W. Boyce, Nicholas Murgolo, Christopher J. Bungard, Matthew Zimmerman, Véronique Dartois, Martin Gengenbacher, David B. Olsen, Thomas Dick	9
4	Structure activity relationship of N-1 substituted 1,5-naphthyrid-2-one analogs of oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents (Part-9) 2022 ·Bioorganic & Medicinal Chemistry Letters ·Sheo B. Singh, Christopher M. Tan, David E. Kaelin, Peter T. Meinke, Lynn Miesel, David B. Olsen, Hideyuki Fukuda, Ryuta Kishii, Masaya Takei, Kohei Ohata, Tomoko Takeuchi, (unknown), Hisashi Takano, (unknown), Yasumichi Fukuda	3
5	DNA-Dependent Binding of Nargenicin to DnaE1 Inhibits Replication in Mycobacterium tuberculosis 2022 ·ACS Infectious Diseases ·(unknown), Mandy K. Mason, (unknown), (unknown), Garth L. Abrahams, (unknown), (unknown), Jon Ambler, Katherine Young, Brendan M. Crowley, David B. Olsen, Digby F. Warner, Clifton E. Barry, Helena I. Boshoff, Meindert H. Lamers, Valerie Mizrahi	17
6	Generation of SARS-CoV-2 reporter replicon for high-throughput antiviral screening and testing 2021 ·Proceedings of the National Academy of Sciences ·Xi He, Shuo Quan, Min Xu, (unknown), Shih Lin Goh, Jiajie Wei, Arthur Fridman, Kenneth A. Koeplinger, Steve S. Carroll, Jay A. Grobler, Amy S. Espeseth, David B. Olsen, Daria J. Hazuda, Dai Wang	58
7	Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis 2019 ·BMC Research Notes ·Trygve Holmøy, Børre Fevang, David B. Olsen, Olav Spigset, Lars Bø	37
8	Discovery and Structure–Activity-Relationship Study of N-Alkyl-5-hydroxypyrimidinone Carboxamides as Novel Antitubercular Agents Targeting Decaprenylphosphoryl-β-d-ribose 2′-Oxidase 2018 ·Journal of Medicinal Chemistry ·Sangmi Oh, Yumi Park, Curtis A. Engelhart, Joshua B. Wallach, Dirk Schnappinger, Kriti Arora, (unknown), (unknown), Hongwu Wang, Nicholas Murgolo, David B. Olsen, Michael Goodwin, (unknown), Dominique J. Wiener, Laura E. Via, Helena I. Boshoff, Clifton E. Barry	29
9	Affinity Selection–Mass Spectrometry Identifies a Novel Antibacterial RNA Polymerase Inhibitor 2017 ·ACS Chemical Biology ·Scott S. Walker, David Degen, Elliott Nickbarg, Donna Carr, Aileen Soriano, (unknown), Ronald E. Painter, Payal R. Sheth, Li Xiao, Xinwei Sher, Nicholas Murgolo, Jing Su, David B. Olsen, Richard H. Ebright, Katherine Young	14
10	PD-1 Blockade in Rhesus Macaques: Impact on Chronic Infection and Prophylactic Vaccination 2009 ·The Journal of Immunology ·Adam C. Finnefrock, Aimin Tang, Fengsheng Li, Daniel C. Freed, Meizhen Feng, Kara S. Cox, Kara J. Sykes, James P. Guare, Michael D. Miller, David B. Olsen, Daria J. Hazuda, John W. Shiver, Danilo R. Casimiro, Tong‐Ming Fu	100
11	Synthesis and HCV inhibitory properties of 9-deaza- and 7,9-dideaza-7-oxa-2′-C-methyladenosine 2007 ·Bioorganic & Medicinal Chemistry ·Gabor Butora, David B. Olsen, Steven S. Carroll, Daniel R. McMasters, Christoph Schmitt, Joseph F. Leone, Mark W. Stahlhut, Christine Burlein, Malcolm MacCoss	24
12	X-ray Crystallographic and Site-directed Mutagenesis Analysis of the Mechanism of Schiff-base Formation in Phosphonoacetaldehyde Hydrolase Catalysis 2004 ·Journal of Biological Chemistry ·Marc C. Morais, Guofeng Zhang, Wenhai Zhang, David B. Olsen, Debra Dunaway‐Mariano, Karen N. Allen	34
13	Assay for Influenza Virus Endonuclease Using DNA Polymerase Extension of a Specific Cleavage Product 1995 ·Analytical Biochemistry ·James L. Cole, Lawrence C. Kuo, David B. Olsen	2
14	[8] Direct sequencing of polymerase chain reaction products 1993 ·Methods in enzymology on CD-ROM/Methods in enzymology ·David B. Olsen, Gerhard Wunderlich, A. Uy, F. Eckstein	3
15	Immobilized Albumin-Immunoglobulin G for Improved Hemocompatibility of Biopolymers 1989 ·ASAIO Transactions ·Sameer Mohammad, David B. Olsen	3
16	Enhanced bacterial adhesion on surfaces pretreated with fibrinogen and fibronectin. 1988 ·PubMed ·Sameer Mohammad, Neal S. Topham, G. Leonard Burns, David B. Olsen	14
17	Blood pump with a magnetically suspended impeller. 1985 ·PubMed ·David B. Olsen, (unknown)	18
18	Insignificant blood damage in calves with a total artificial heart up to six months. 1978 ·PubMed ·(unknown), (unknown), (unknown), (unknown), (unknown), David B. Olsen, (unknown), Kolff Wj	9
19	Comparison of pneumatic and electrically powered total artificial hearts in vivo. 1978 ·PubMed ·(unknown), (unknown), (unknown), (unknown), (unknown), David B. Olsen, (unknown), Kolff Wj	6
20	A comparsion of polyurethane and silastic artificial hearts in 10 long survival experiments in calves. 1975 ·PubMed ·(unknown), David B. Olsen, E. J. Hershgold, (unknown), (unknown), Kolff Wj	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact